| Title: |
166Ho-RadioEmbolizaTiOn Using personalized prediCtive dosimetry in patients with Hepatocellular carcinoma: A prospective, single-centre study (RETOUCH) |
| Authors: |
Bucalau, Ana-Maria; Collette, Benoit; Tancredi, I.; Vierasu, Ortansa-Irina; Tannouri, Fadi; Pezzulo, Martina; Moreno Reyes, Mario Rodrigo; Verset, Gontran |
| Source: |
Liver international |
| Publication Year: |
2024 |
| Collection: |
DI-fusion : dépôt institutionnel de l'Université libre de Bruxelles (ULB) |
| Subject Terms: |
Imagerie médicale; radiologie; tomographie; Isotopes et éléments radioactifs; Physique atomique et nucléaire; hepatocellular carcinoma (HCC); Holmium-166 (166Ho); personalized dosimetry; radioembolization |
| Description: |
Background and Aims: Holmium-166 (166Ho) radioembolization could offer a more individualized approach in terms of imaging and dosimetry. We aim to evaluate the feasibility and safety of 166Ho selective internal radiation therapy (SIRT) using a higher tumour dose than previously administered determined by 166Ho-scout as a surrogate marker in HCC patients. Methods: This is an open-label, prospective, non-randomized, single-centre pilot study that included patients with HCC that received 166Ho-SIRT if the work-up using 166Ho-scout showed a tumour-absorbed dose ≥150 Gy, a non-tumoural liver absorbed dose less than 60 Gy and a lung absorbed dose less than 30 Gy. Primary endpoints were feasibility and safety–toxicity profiles at 24–48 h and 1 month. Overall response rates (ORR) at 3 months (mRECIST, RECIST 1.1 and metabolic response by FDG and choline PET CT) and time to progression (TTP) represented the secondary endpoints. Results: Fifteen patients with large tumours (mean diameter 55.67 ± 28.42 mm) received 17 166Ho-SIRT treatments between July 2020 and June 2022. All the attempted treatments were accomplished. Mean administered tumour dose was 183.18 ± 71.71 Gy, while non-tumour liver dose was 30.29 ± 14.56 Gy. Median time of follow-up was 12 months (IQR 9–16). Only grade 1–2 clinical and biological AEs were observed. There were no liver decompensations. At 3 months, objective response was achieved for all target lesions (CR 78.57%, PR 21.43% according to mRECIST). Median TTP was 18.8 (range 2.9; n.e.) months. Conclusion: Personalized 166Ho-SIRT with a tumour delivered dose ≥150 Gy was feasible and safe for HCC patients with promising response rates. ; SCOPUS: ar.j ; info:eu-repo/semantics/published |
| Document Type: |
article in journal/newspaper |
| File Description: |
1 full-text file(s): application/pdf |
| Language: |
English |
| Relation: |
uri/info:doi/10.1111/liv.15923; uri/info:pmid/39569818; uri/info:scp/85210012819; https://dipot.ulb.ac.be/dspace/bitstream/2013/385216/3/Bucalau2024.pdf |
| Availability: |
https://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/385216; https://dipot.ulb.ac.be/dspace/bitstream/2013/385216/3/Bucalau2024.pdf |
| Accession Number: |
edsbas.E96F837D |
| Database: |
BASE |